Corporate GovernanceApr 29, 2026, 04:55 PM
SNTI Files 10-K/A for Corporate Governance; Reorganization Noted
AI Summary
Senti Biosciences, Inc. filed Amendment No. 1 to its Form 10-K to include Part III information (Items 10, 11, 12, 13, and 14) as its definitive proxy statement will not be filed within 120 days of the fiscal year-end. The filing also notes the previously disclosed holding company reorganization on April 24, 2026, which made the Company the successor registrant. New certifications from the CEO and CFO are included, and the amendment details the company's corporate governance structure, executive compensation, and director compensation policies.
Key Highlights
- Senti Biosciences, Inc. filed Amendment No. 1 to its Form 10-K.
- Amendment provides Part III items (10-14) due to delayed definitive proxy statement filing.
- Company became successor registrant following April 24, 2026 holding company reorganization.
- New certifications from the Chief Executive Officer and Chief Financial Officer were filed.
- Non-employee directors receive an annual retainer of $35,000.
- Initial stock option award for non-employee directors is 43,900 shares of common stock.
- Board of Directors met 7 times in 2025; Audit Committee met 4 times, Compensation Committee 2 times.
Price Impact
More from SNTI